Anti-VEGF Therapy with Bevacizumab - Limited Cardiovascular Toxicity

  • Yu, Jing (Department of Cardiology, Cangzhou Central Hospital of HeBei) ;
  • Cao, Xu-Fen (Department of Cardiology, Cangzhou Central Hospital of HeBei) ;
  • Zheng, Ye (Department of Cardiology, Cangzhou Central Hospital of HeBei) ;
  • Zhao, Rong-Cheng (Department of Cardiology, Cangzhou Central Hospital of HeBei) ;
  • Yan, Li-Qiu (Department of Cardiology, Cangzhou Central Hospital of HeBei) ;
  • Zhao, Lei (Department of Cardiology, Cangzhou Central Hospital of HeBei) ;
  • Wang, Jia-Wang (Department of Cardiology, Cangzhou Central Hospital of HeBei)
  • Published : 2015.01.22


Purpose: This analysis was conducted to evaluate cardiovascular toxicity of commonly used anti-VEGF therapeutic agent, bevacizumab, in treating patients with cancer. Methods: Clinical studies evaluating the efficacy and safety of bevacizumab-based regimens on response and safety for patients with cancer were identified using a predefined search strategy, allowing cardiovascular toxicity and other side effects of treatment to be estimated. Results: In bevacizumab based regimens, 4 clinical studies including 282 patients with advanced cancer (including gliomas, cervical, breast and ovarian cancer) were considered eligible for inclusion. These bevacizumab-based regimens included docetaxel, irinitecan and carboplatin. Systematic analysis suggested that, of 282 patients treated by bevacizumab based regimens, hypertension and thrombo-embolism occurred in 2.5% (7/282), while only 3 patients reported cardiovascular events (1.1%). No treatment related death occurred in bevacizumab based treatment. Conclusion: This systemic analysis suggests that bevacizumab based regimens are associated with reasonable and accepted cardiovascular toxicity when treating patients with gliomas, cervical, breast and ovarian cancer.


  1. Abaid LN1, Lopez KL, Micha JP, et al (2010). Bevacizumab, paclitaxel and carboplatin for advanced ovarian cancer: low risk of gastrointestinal and cardiovascular toxicity. Eur J Gynaecol Oncol, 31, 308-11.
  2. Alam M, Ratner D (2001). Cutaneous squamous-cell carcinoma. N Engl J Med, 344, 975-83.
  3. Bleomycin in advanced squamous cell carcinoma: A random controlled trial (1976). Report of Medical Research Council Working Party on Bleomycin. Br Med J, 1, 188-90.
  4. Bristol-Myers Squibb Company: Sprycel (Dasatinib) prescribing information. Princeton, NJ, 2006.
  5. Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol, 24, 3354-60.
  6. Clayman GL, Lee JJ, Holsinger FC, et al (2005). Mortality risk from squamous cell skin cancer. J Clin Oncol, 23, 759-65.
  7. Lippman SM, Parkinson DR, Itri LM et al. 13-cis-retinoic acid and interferon alpha-2a: Effective combination therapy for advanced squamous cell.
  8. Cranmer LD, Engelhardt C, Morgan SS et al (2010). Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist, 15, 1320-8.
  9. D'Adamo DR, Anderson SE, Albritton K, et al (2005). Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol, 23, 7135-42
  10. Deng QQ, Huang XE, Ye LH, et al (2013). Phase II trial of $Loubo^{(R)}$ (Lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes. Asian Pac J Cancer Prev, 14, 413-7.
  11. Deng W, Long L, Li JL, et al (2014). Mortality of major cancers in guangxi, china: sex, age and geographical differences from 1971 and 2005. Asian Pac J Cancer Prev, 15, 1567-74.
  12. Ewer MS, Lippman SM (2005). Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol, 23, 2900-2.
  13. Fan JH, Wang JB, Jiang Y, et al (2014). Attributable Causes of Liver Cancer Mortality and Incidence in China. Asian Pac J Cancer Prev, 14, 7251-6
  14. Fujisawa Y, Umebayashi Y, Ichikawa E, et al (2006). Chemoradiation using lowdose cisplatin and 5-fluorouracil in locally advanced squamous cell carcinoma of the skin: A report of two cases. J Am Acad Dermatol, 55, S81-5.
  15. Guiu S, Taillibert S, Chinot O et al (2008). Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study. Rev Neurol, 164, 588-94.
  16. Goldberg H, Tsalik M, Bernstein Z, et al (1994). Cisplatin-based chemotherapy for advanced basal and squamous cell carcinomas. Harefuah, 127, 217-21.
  17. Guthrie TH Jr, McElveen LJ, Porubsky ES, et al (1985). Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer, 55, 1629-32.<1629::AID-CNCR2820550802>3.0.CO;2-I
  18. Guthrie TH Jr, Porubsky ES, Luxenberg MN, et al (1990). Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: Results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol, 8, 342-6.
  19. Han A, Ratner D (2007). What is the role of adjuvant radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion? Cancer, 109, 1053-9.
  20. Hao ZF, Ao JH, Zhang J, et al (2013). ATF3 activates Stat3 phosphorylation through inhibition of p53 expression in skin cancer cells. Asian Pac J Cancer Prev, 14, 7439-44.
  21. Hedrick E, Kozloff M, Hainsworth J, et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results froma large observational registry in the US (BRiTE). J Clin Oncol 2006, 24 (suppl), 155s (abstract 3536).
  22. Hurwitz H, Fehrenbacher L, Novotny W, et al (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350, 2335-42.
  23. Ikegawa S, Saida T, Obayashi H, et al (2013). Cisplatin combination chemotherapy in squamous cell carcinoma and adenoid cystic carcinoma of the skin. J Dermatol, 16, 227-30.
  24. Joseph MG, Zulueta WP, Kennedy PJ, et al (1992). Squamous cell carcinoma of the skin of the trunk and limbs: The incidence of metastases and their outcome. Aust N Z J Surg, 62, 697-701.
  25. Jambusaria-PahlajaniA, Miller CJ, QuonH, et al (2009). Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: A systematic review of outcomes. Dermatol Surg, 35, 574-85.
  26. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al (2003). Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol, 21, 60-5.
  27. Kerkela R, Grazette L, Yacobi R, et al (2006). Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med, 12, 908-16.
  28. Khansur T, Kennedy A (1991). Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer, 67, 2030-32.<2030::AID-CNCR2820670803>3.0.CO;2-K
  29. Merimsky O, Neudorfer M, Spitzer E, et al (1992). Salvage cisplatin and adriamycin for advanced or recurrent basal or squamous cell carcinoma of the face. Anticancer Drugs, 3, 481-4.
  30. Miller AB, Hoogstraten B, Staquet M, et al (1981). Reporting results of cancer treatment. Cancer, 47, 207-14.<207::AID-CNCR2820470134>3.0.CO;2-6
  31. Miller DL, Weinstock MA, et al (1994). Nonmelanoma skin cancer in the United States: Incidence. J Am Acad Dermatol, 30, 774-8.
  32. Minton TJ, et al (2008). Contemporary Mohs surgery applications. Curr Opin Otolaryngol Head Neck Surg, 16, 376-80.
  33. Mohs F, et al (1978). Chemosurgery: Microscopically Controlled Surgery for Skin Cancer. Springfield, IL: Charles C. Thomas, 153-64.
  34. Monk BJ, Sill MW, Burger RA et al (2009). Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol, 27, 1069-74.
  35. Motzer RJ, Michaelson MD, Redman BG, et al (2006). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 24, 16-24.
  36. Nakamura K, Okuyama R, Saida T, et al (2013). Platinum and anthracycline therapy for advanced cutaneous squamous cell carcinoma. Int J Clin Oncol, 18, 506-9.
  37. Pivot X, Schneeweiss A, Verma S et al (2011). Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. Eur J Cancer, 47, 2387-95.
  38. Sadek H, Azli N, Wendling JL, et al (1990). Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer, 66, 1692-6.<1692::AID-CNCR2820660807>3.0.CO;2-Y
  39. Shih T, Lindley C (2006). Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther, 28, 1779-802.
  40. Shin DM, Glisson BS, Khuri FR, et al (2002). Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol, 20, 364-70.
  41. Veness MJ, Morgan GJ, Palme CE, et al (2005). Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: Combined treatment should be considered best practice. Laryngoscope, 115, 870-5.
  42. Von Hoff DD, Layard MW, Basa P, et al (1979). Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med, 91, 710-7.
  43. Wu Q, Zhao YB, Sun ZH, et al (2013). Clinical application of endoscopic inguinal lymph node resection after lipolysis and liposuction for vulvar cancer. Asian Pac J Cancer Prev, 14, 7121-6.Yeh ET. Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med, 57, 485-98.
  44. Yeh ET, Tong AT, Lenihan DJ, et al (2004). Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation, 109, 3122-31.

Cited by

  1. Retrospective Evaluation of Thromboembolism Risk in Ovarian Cancer Patients Treated with Bevacizumab vol.12, pp.4, 2017,